WASHINGTON — Pharmaceutical giant Pfizer is suing the Trump administration over two long-standing Medicare rules that Pfizer says are blocking it from helping seniors pay for an expensive heart condition drug.

The lawsuit, which was filed in a federal court in New York Friday, concerns two planned copay assistance programs for Pfizer’s drug tafamidis, which treats a rare fatal heart disease, transthyretin amyloid cardiomyopathy. The company is hoping to overturn two long-standing federal policies: one that prevents drug makers from directly paying part of seniors’ drug bills, and another that keeps drug makers from coordinating directly with outside charities that offer similar programs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy